US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
CA2539253A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
US20060046962A1
(en)
|
2004-08-25 |
2006-03-02 |
Aegis Therapeutics Llc |
Absorption enhancers for drug administration
|
US8268791B2
(en)
*
|
2004-08-25 |
2012-09-18 |
Aegis Therapeutics, Llc. |
Alkylglycoside compositions for drug administration
|
US20140162965A1
(en)
|
2004-08-25 |
2014-06-12 |
Aegis Therapeutics, Inc. |
Compositions for oral drug administration
|
US9895444B2
(en)
|
2004-08-25 |
2018-02-20 |
Aegis Therapeutics, Llc |
Compositions for drug administration
|
US7893017B2
(en)
|
2004-10-07 |
2011-02-22 |
Novo Nordisk A/S |
Protracted GLP-1 compounds
|
JP5107713B2
(ja)
|
2004-10-07 |
2012-12-26 |
ノヴォ ノルディスク アー/エス |
遅延性のエキセンディン−4化合物
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
TWI362392B
(en)
*
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
CN101128214A
(zh)
*
|
2005-03-18 |
2008-02-20 |
诺和诺德公司 |
长效glp-1化合物
|
CN100374462C
(zh)
*
|
2005-11-21 |
2008-03-12 |
大连帝恩生物工程有限公司 |
截短胰高血糖素样肽1(sGLP-1)、制法及其应用
|
EP2007397B1
(en)
|
2006-04-07 |
2013-07-24 |
Merrion Research III Limited |
Solid oral dosage form containing an enhancer
|
US8173594B2
(en)
*
|
2006-06-23 |
2012-05-08 |
Aegis Therapeutics, Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
US8084022B2
(en)
*
|
2006-06-23 |
2011-12-27 |
Aegis Therapeutics, Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
US8226949B2
(en)
*
|
2006-06-23 |
2012-07-24 |
Aegis Therapeutics Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
US7998927B2
(en)
*
|
2006-06-23 |
2011-08-16 |
Aegis Therapeutics, Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
US20090326193A1
(en)
*
|
2006-06-23 |
2009-12-31 |
Aegis Therapeutics Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
US7425542B2
(en)
*
|
2006-06-23 |
2008-09-16 |
Aegis Therapeutics, Inc. |
Stabilizing alkylglycoside compositions and methods thereof
|
ES2532116T3
(es)
*
|
2007-09-05 |
2015-03-24 |
Novo Nordisk A/S |
Péptidos derivados con A-B-C-D y sus usos terapéuticos
|
WO2009030774A1
(en)
*
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Truncated glp-1 derivatives and their therapeutical use
|
EP2679597A1
(en)
|
2007-09-05 |
2014-01-01 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
PL2597103T3
(pl)
|
2007-11-16 |
2017-04-28 |
Novo Nordisk A/S |
Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
|
US20100317057A1
(en)
*
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
PL2254906T3
(pl)
|
2008-03-18 |
2017-04-28 |
Novo Nordisk A/S |
Stabilizowane względem proteaz, acylowane analogi insuliny
|
AU2009228093B2
(en)
|
2008-03-28 |
2014-08-07 |
Neurelis, Inc. |
Administration of benzodiazepine compositions
|
US8999383B2
(en)
|
2008-05-07 |
2015-04-07 |
Merrion Research Iii Limited |
Compositions of GnRH related compounds and processes of preparation
|
BRPI0917000A2
(pt)
*
|
2008-08-06 |
2016-02-16 |
Novo Nordisk Healthcare Ag |
proteínas conjugadas com eficácia in vivo prolongada
|
US8637647B2
(en)
|
2008-09-12 |
2014-01-28 |
Novo Nordisk A/S |
Method of acylating a peptide or protein
|
US8440631B2
(en)
|
2008-12-22 |
2013-05-14 |
Aegis Therapeutics, Llc |
Compositions for drug administration
|
EP2389389B1
(en)
|
2009-01-22 |
2015-04-15 |
Novo Nordisk Health Care AG |
Stable growth hormone compounds
|
CN102361647B
(zh)
|
2009-01-23 |
2018-02-16 |
诺沃-诺迪斯克有限公司 |
具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
|
US20120172298A1
(en)
*
|
2009-06-11 |
2012-07-05 |
Novo Nordisk A/S |
Glp-1 and fgf21 combinations for treatment of diabetes type 2
|
EA022816B1
(ru)
|
2009-07-13 |
2016-03-31 |
Зилэнд Фарма А/С |
Ацилированные аналоги глюкагона
|
US8841249B2
(en)
|
2009-08-06 |
2014-09-23 |
Novo Nordisk A/S |
Growth hormones with prolonged in-vivo efficacy
|
ES2625735T3
(es)
*
|
2009-12-16 |
2017-07-20 |
Novo Nordisk A/S |
Análogos y derivados de GLP-1
|
CA2787895A1
(en)
|
2010-01-22 |
2011-07-28 |
Novo Nordisk Health Care Ag |
Stable growth hormone compounds
|
MX345736B
(es)
|
2010-01-22 |
2017-02-14 |
Novo Nordisk Healthcare Ag |
Hormonas de crecimiento con eficacia in vivo prolongada.
|
US20130012432A1
(en)
|
2010-02-26 |
2013-01-10 |
Novo Nordisk A/S |
Peptides for Treatment of Obesity
|
US9089484B2
(en)
|
2010-03-26 |
2015-07-28 |
Merrion Research Iii Limited |
Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
|
RU2559320C2
(ru)
|
2010-03-26 |
2015-08-10 |
Ново Нордиск А/С |
Новые аналоги глюкагона
|
CN102186881B
(zh)
*
|
2010-04-27 |
2015-04-08 |
贝达药业股份有限公司 |
胰高血糖素样肽-1衍生物及其应用
|
CA2797431C
(en)
*
|
2010-04-27 |
2016-06-21 |
Zhejiang Beta Pharma Inc. |
Glucagon-like peptide-1 analogue and use thereof
|
KR101609302B1
(ko)
*
|
2010-05-17 |
2016-04-06 |
베타 파머수티컬 컴퍼니 리미티드 |
새로운 글루카곤 유사 펩타이드 유사체, 조성물, 및 사용 방법
|
WO2012016419A1
(zh)
*
|
2010-08-06 |
2012-02-09 |
浙江贝达药业有限公司 |
Glp-1衍生物及其应用
|
US9006178B2
(en)
|
2010-11-09 |
2015-04-14 |
Novo Nordisk A/S |
Double-acylated GLP-1 derivatives with a linker
|
JP5902194B2
(ja)
|
2010-12-16 |
2016-04-13 |
ノヴォ ノルディスク アー/エス |
Glp−1アゴニストとn−(8−(2−ヒドロキシベンゾイル)アミノ)カプリル酸の塩とを含む固形組成物
|
KR20140026354A
(ko)
|
2011-01-07 |
2014-03-05 |
메리온 리서치 Ⅲ 리미티드 |
경구 투여용 철의 제약 조성물
|
US20140004198A1
(en)
|
2011-01-19 |
2014-01-02 |
Novo Nordisk A/S |
Glp-1 particles and compositions
|
US20140045754A1
(en)
|
2011-01-19 |
2014-02-13 |
Joern Drustrup |
Glp-1 compositions
|
AU2012234276A1
(en)
*
|
2011-03-28 |
2013-08-29 |
Novo Nordisk A/S |
Novel glucagon analogues
|
JP5871905B2
(ja)
*
|
2011-03-30 |
2016-03-01 |
ベータ ファーマシューティカルズ カンパニー リミテッド |
グルカゴン様ペプチド−1類似体およびその使用
|
KR102093463B1
(ko)
*
|
2011-04-12 |
2020-03-26 |
노보 노르디스크 에이/에스 |
이중 아실화된 glp-1 유도체
|
ES2612278T3
(es)
|
2011-04-12 |
2017-05-16 |
Novo Nordisk A/S |
Derivados de GLP-1 doble-acilados
|
EP2734239A2
(en)
|
2011-07-18 |
2014-05-28 |
Arts Biologics A/S |
Long acting luteinizing hormone (lh) compound
|
CN107266558A
(zh)
|
2011-09-06 |
2017-10-20 |
诺沃—诺迪斯克有限公司 |
Glp‑1衍生物
|
JP6352806B2
(ja)
|
2011-09-23 |
2018-07-04 |
ノヴォ ノルディスク アー/エス |
新規のグルカゴン類似体
|
RU2643515C2
(ru)
|
2011-12-29 |
2018-02-02 |
Ново Нордиск А/С |
Дипептид, содержащий непротеиногенную аминокислоту
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
RS57827B1
(sr)
|
2012-02-15 |
2018-12-31 |
Novo Nordisk As |
Antitela koja vezuju protein 1 prepoznavanja peptidoglikana
|
EP3196214B1
(en)
|
2012-02-15 |
2019-07-31 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
|
KR102266299B1
(ko)
*
|
2012-03-22 |
2021-06-18 |
노보 노르디스크 에이/에스 |
Glp-1 펩티드의 조성물 및 그것의 제조
|
ES2952874T3
(es)
|
2012-03-22 |
2023-11-06 |
Novo Nordisk As |
Composiciones de péptidos GLP-1 y preparación de estas
|
JP6356660B2
(ja)
|
2012-03-22 |
2018-07-11 |
ノヴォ ノルディスク アー/エス |
送達剤を含む組成物およびその調製
|
PT2827845T
(pt)
|
2012-03-22 |
2019-03-29 |
Novo Nordisk As |
Composições compreendendo um agente de entrega e sua preparação
|
EA028665B1
(ru)
|
2012-05-03 |
2017-12-29 |
Зилэнд Фарма А/С |
Соединения - двойные агонисты gip-glp-1 и способы
|
US11274135B2
(en)
*
|
2012-05-08 |
2022-03-15 |
Novo Nordisk A/S |
Double-acylated GLP-1 derivatives
|
WO2013167454A1
(en)
|
2012-05-08 |
2013-11-14 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
WO2013170636A1
(zh)
|
2012-05-18 |
2013-11-21 |
爱德迪安(北京)生物技术有限公司 |
用于糖尿病治疗的蛋白、蛋白缀合物及其应用
|
JP6517690B2
(ja)
*
|
2012-06-20 |
2019-05-22 |
ノヴォ ノルディスク アー/エス |
ペプチド及び送達剤を含む錠剤製剤
|
CA2877056A1
(en)
*
|
2012-07-01 |
2014-01-09 |
Novo Nordisk A/S |
Use of long-acting glp-1 peptides
|
AR091866A1
(es)
|
2012-07-23 |
2015-03-04 |
Zealand Pharma As |
Analogos del glucagon
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
US20150273069A1
(en)
*
|
2012-10-17 |
2015-10-01 |
Novo Nordisk A/S |
Fatty acid acylated amino acids for oral peptide delivery
|
JP6464145B2
(ja)
|
2013-04-05 |
2019-02-06 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
成長ホルモン化合物製剤
|
JP6594856B2
(ja)
|
2013-04-18 |
2019-10-23 |
ノヴォ ノルディスク アー/エス |
医療用の安定な遷延性glp−1/グルカゴン受容体コアゴニスト
|
MY172578A
(en)
|
2013-05-02 |
2019-12-03 |
Novo Nordisk As |
Oral dosing of glp-1 compounds
|
EP3010546B1
(en)
|
2013-06-20 |
2017-08-09 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
AU2014286234A1
(en)
|
2013-07-04 |
2015-12-17 |
Novo Nordisk A/S |
Derivatives of GLP-1 like peptides, and uses thereof
|
CN105451776B
(zh)
|
2013-08-15 |
2020-04-17 |
诺和诺德股份有限公司 |
Glp-1衍生物及其用途
|
GB201315335D0
(en)
|
2013-08-29 |
2013-10-09 |
Of Singapore |
Amino diacids containing peptide modifiers
|
US10286078B2
(en)
|
2013-09-13 |
2019-05-14 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
ES2688708T3
(es)
|
2013-10-17 |
2018-11-06 |
Zealand Pharma A/S |
Análogos de glucagón acilados
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
MX2016005556A
(es)
|
2013-11-06 |
2016-07-15 |
Zealand Pharma As |
Compuestos agonistas duales de gip-glp-1 y procedimientos.
|
CN105829339B
(zh)
|
2013-11-06 |
2021-03-12 |
西兰制药公司 |
胰高血糖素-glp-1-gip三重激动剂化合物
|
WO2015081891A1
(en)
|
2013-12-06 |
2015-06-11 |
Baikang (Suzhou) Co., Ltd |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
CN106456589B
(zh)
*
|
2013-12-18 |
2020-07-07 |
斯克利普斯研究所 |
修饰的治疗剂、订合的肽脂质缀合物及其组合物
|
EP3107560A1
(en)
|
2014-02-18 |
2016-12-28 |
Novo Nordisk A/S |
Stable glucagon analogues and use for treatment of hypoglycaemia
|
WO2015155151A1
(en)
|
2014-04-07 |
2015-10-15 |
Novo Nordisk A/S |
Double-acylated glp-1 compounds
|
CN106999553B
(zh)
|
2014-05-07 |
2021-11-26 |
诺和诺德股份有限公司 |
使用glp-1和抗-il-21对1型糖尿病的治疗
|
WO2015185640A1
(en)
|
2014-06-04 |
2015-12-10 |
Novo Nordisk A/S |
Glp-1/glucagon receptor co-agonists for medical use
|
LT3172232T
(lt)
|
2014-07-17 |
2024-02-12 |
Novo Nordisk A/S |
Į vietą nukreipta trem-1 antikūnų mutagenezė, skirta klampumui sumažinti
|
EP3530671A3
(en)
|
2014-09-05 |
2019-11-13 |
University of Copenhagen |
Gip peptide analogues
|
GR20140100479A
(el)
*
|
2014-09-23 |
2016-05-05 |
Novetide, Ltd., |
Συνθεση λιραγλουτιδης
|
DK3006045T3
(en)
|
2014-10-07 |
2017-07-17 |
Cyprumed Gmbh |
Pharmaceutical formulations for oral administration of peptide or protein drugs
|
JP6898231B6
(ja)
|
2014-10-29 |
2021-07-28 |
ジーランド ファーマ アクティーゼルスカブ |
Gipアゴニスト化合物及び方法
|
WO2016083499A1
(en)
|
2014-11-27 |
2016-06-02 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
EP3233898A1
(en)
|
2014-12-17 |
2017-10-25 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
TWI681966B
(zh)
|
2014-12-23 |
2020-01-11 |
丹麥商諾佛 儂迪克股份有限公司 |
Fgf21衍生物及其用途
|
JP7211704B2
(ja)
*
|
2015-01-29 |
2023-01-24 |
ノヴォ ノルディスク アー/エス |
Glp-1アゴニスト及び腸溶コーティングを含む錠剤
|
WO2016120380A1
(en)
*
|
2015-01-29 |
2016-08-04 |
Novo Nordisk A/S |
Pharmaceutical composition for oral glp-1 administration comprising a tablet core and immediate release coating
|
AU2016247499B2
(en)
|
2015-04-16 |
2020-09-03 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
BR112017026853A2
(pt)
*
|
2015-06-16 |
2018-08-14 |
Sun Pharma Advanced Research Company Limited |
composição de ação prolongada
|
EP3310376A4
(en)
|
2015-06-17 |
2019-01-23 |
The California Institute for Biomedical Research |
MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
|
CN106554403B
(zh)
*
|
2015-09-25 |
2021-08-31 |
博瑞生物医药(苏州)股份有限公司 |
艾塞那肽修饰物及其用途
|
CN106554408A
(zh)
*
|
2015-09-30 |
2017-04-05 |
天津药物研究院有限公司 |
长效胰高血糖素样肽-1类似物二聚体及其应用
|
CN106554409B
(zh)
*
|
2015-09-30 |
2020-04-07 |
天津药物研究院有限公司 |
一种长效胰高血糖素样肽-1类似物及其应用
|
AU2016335287A1
(en)
|
2015-10-07 |
2018-04-12 |
Cyprumed Gmbh |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
CN106928343A
(zh)
*
|
2015-12-30 |
2017-07-07 |
深圳翰宇药业股份有限公司 |
索玛鲁肽的制备方法
|
US10946074B2
(en)
|
2016-03-03 |
2021-03-16 |
Novo Nordisk A/S |
GLP-1 derivatives and uses thereof
|
CN107266557B
(zh)
*
|
2016-04-06 |
2020-04-07 |
天津药物研究院有限公司 |
一种聚乙二醇修饰的胰高血糖素样肽-1类似物
|
JP7221694B2
(ja)
*
|
2016-04-28 |
2023-02-14 |
ノヴォ ノルディスク アー/エス |
心血管状態におけるセマグルチド
|
WO2018065634A1
(en)
|
2016-10-07 |
2018-04-12 |
Cyprumed Gmbh |
Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
|
WO2018078112A1
(en)
|
2016-10-27 |
2018-05-03 |
Aarhus Universitet |
Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
|
MA46780A
(fr)
|
2016-11-07 |
2019-09-11 |
Novo Nordisk As |
Esters à dchbs actif de composés peg et leur utilisation
|
EP3554534B1
(en)
|
2016-12-16 |
2021-06-23 |
Novo Nordisk A/S |
Insulin containing pharmaceutical compositions
|
CN107033234B
(zh)
*
|
2017-01-03 |
2018-06-26 |
北京凯因科技股份有限公司 |
酰化的glp-1衍生物
|
CA3055759A1
(en)
|
2017-03-08 |
2018-09-13 |
Intarcia Therapeutics, Inc. |
Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
|
US11572399B2
(en)
|
2017-05-31 |
2023-02-07 |
University Of Copenhagen |
Long-acting GIP peptide analogues
|
TWI797133B
(zh)
|
2017-06-09 |
2023-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
用於經口投予的固體組成物
|
CN109248323B
(zh)
*
|
2017-07-14 |
2023-09-08 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
CN110945017A
(zh)
*
|
2017-07-19 |
2020-03-31 |
诺沃挪第克公司 |
双功能化合物
|
WO2019038412A1
(en)
*
|
2017-08-24 |
2019-02-28 |
Novo Nordisk A/S |
GLP-1 COMPOSITIONS AND USES THEREOF
|
CN111163795A
(zh)
|
2017-09-10 |
2020-05-15 |
诺沃挪第克公司 |
用于治疗肥胖症的mic-1和glp-1
|
CN111164128A
(zh)
|
2017-09-29 |
2020-05-15 |
韩美药品株式会社 |
包含作为接头的非肽基聚合物偶联的脂肪酸衍生物化合物的蛋白复合物及其制备方法
|
BR112020006246A2
(pt)
|
2017-10-12 |
2021-03-30 |
Novo Nordisk A/S |
Método para controle do peso de um sujeito em necessidade
|
CN107881187A
(zh)
*
|
2017-11-20 |
2018-04-06 |
珠海联邦制药股份有限公司 |
将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
|
WO2019120639A1
(en)
|
2017-12-21 |
2019-06-27 |
Bachem Holding Ag |
Solid phase synthesis of acylated peptides
|
JP6898518B2
(ja)
|
2018-02-02 |
2021-07-07 |
ノヴォ ノルディスク アー/エス |
Glp−1アゴニスト、n−(8−(2−ヒドロキシベンゾイル)アミノ)カプリル酸の塩及び滑沢剤を含む固形組成物
|
WO2019157099A1
(en)
|
2018-02-06 |
2019-08-15 |
Aegis Therapeutics, Llc |
Intranasal epinephrine formulations and methods for the treatment of disease
|
CN110294800B
(zh)
*
|
2018-03-22 |
2022-03-04 |
齐鲁制药有限公司 |
一种索玛鲁肽的制备方法
|
JP2021519594A
(ja)
|
2018-04-02 |
2021-08-12 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
抗trem−1抗体およびその使用
|
AU2019247936C1
(en)
|
2018-04-05 |
2023-06-15 |
Sun Pharmaceutical Industries Limited |
Novel GLP-1 analogues
|
US20210087250A1
(en)
|
2018-04-06 |
2021-03-25 |
Cyprumed Gmbh |
Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
|
CN115814064A
(zh)
*
|
2018-04-19 |
2023-03-21 |
杭州先为达生物科技有限公司 |
Glp-1衍生物及其治疗用途
|
WO2019200594A1
(zh)
*
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
PE20210473A1
(es)
|
2018-05-04 |
2021-03-08 |
Novo Nordisk As |
Derivados de gip y usos de estos
|
TWI829687B
(zh)
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
|
CA3116271A1
(en)
|
2018-10-26 |
2020-04-30 |
Novo Nordisk A/S |
Stable semaglutide compositions and uses thereof
|
CN109180801B
(zh)
*
|
2018-11-01 |
2021-08-13 |
汉肽生物医药集团有限公司 |
一种合成索玛鲁肽的方法
|
WO2020127476A1
(en)
|
2018-12-19 |
2020-06-25 |
Krka, D.D., Novo Mesto |
Pharmaceutical composition comprising glp-1 analogue
|
EP3897582A1
(en)
|
2018-12-21 |
2021-10-27 |
Novo Nordisk A/S |
Process of spray drying of glp-1 peptide
|
CN113329810A
(zh)
|
2019-01-24 |
2021-08-31 |
诺和诺德股份有限公司 |
辊压机和使用辊压机的干法制粒方法
|
WO2020168017A1
(en)
|
2019-02-12 |
2020-08-20 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
CN113454211A
(zh)
|
2019-02-20 |
2021-09-28 |
诺和诺德股份有限公司 |
氨酰基-tRNA合成酶及其用途
|
WO2020187712A1
(en)
|
2019-03-15 |
2020-09-24 |
Novo Nordisk A/S |
Process for spray drying a glp-1 peptide
|
WO2020190757A1
(en)
|
2019-03-15 |
2020-09-24 |
Novetide Ltd. |
Improved processes for the preparation of semaglutide
|
CN111748019A
(zh)
*
|
2019-03-29 |
2020-10-09 |
深圳翰宇药业股份有限公司 |
一种多肽衍生化合物的合成方法
|
WO2020201280A1
(en)
|
2019-04-01 |
2020-10-08 |
Novo Nordisk A/S |
Antibodies directed against liraglutide and use thereof
|
CN111909256A
(zh)
*
|
2019-05-10 |
2020-11-10 |
宁波鲲鹏生物科技有限公司 |
多肽衍生物及其制备方法
|
CN114340655A
(zh)
|
2019-09-02 |
2022-04-12 |
诺和诺德股份有限公司 |
生产包含glp-1肽的片剂的方法
|
CN110590934B
(zh)
*
|
2019-09-25 |
2020-12-08 |
北京乐普医药科技有限公司 |
一种glp-1化合物
|
CN114728042A
(zh)
|
2019-11-06 |
2022-07-08 |
诺和诺德股份有限公司 |
用于痴呆的glp-1受体激动剂
|
EP3819308A1
(en)
|
2019-11-07 |
2021-05-12 |
Fresenius Kabi iPSUM S.r.l. |
Process for the manufacture of derivatized amino acids
|
US20220395559A1
(en)
|
2019-11-07 |
2022-12-15 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
WO2021105393A1
(en)
|
2019-11-29 |
2021-06-03 |
Novo Nordisk A/S |
Processes for obtaining stable glp-1 compositions
|
WO2021123228A1
(en)
|
2019-12-18 |
2021-06-24 |
Krka, D.D., Novo Mesto |
Pharmaceutical composition comprising glp-1 analogue
|
BR112022013042A2
(pt)
*
|
2019-12-30 |
2022-10-18 |
Gan & Lee Pharmaceuticals Co Ltd |
Composto da fórmula b, formulação farmacêutica, composição farmacêutica, método para tratar ou prevenir hiperglicemia, diabetes e/ou obesidade
|
EP4085077A4
(en)
|
2019-12-31 |
2024-01-17 |
Beijing Ql Biopharmaceutical Co Ltd |
FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
|
WO2021139744A1
(en)
|
2020-01-11 |
2021-07-15 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Conjugates of fusion proteins of glp-1 and fgf21
|
CN115484935A
(zh)
|
2020-02-14 |
2022-12-16 |
G2G生物公司 |
包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物
|
CN111253475B
(zh)
*
|
2020-02-18 |
2021-03-09 |
江苏诺泰澳赛诺生物制药股份有限公司 |
Glp-1激动多肽化合物及其盐与合成方法及用途
|
AU2021207313A1
(en)
|
2020-02-18 |
2022-07-28 |
Novo Nordisk A/S |
Pharmaceutical formulations
|
US20230295077A1
(en)
|
2020-04-10 |
2023-09-21 |
Fresenius Kabi Oncology Limited |
An improved process for the preparation of semaglutide side chain
|
US11478533B2
(en)
|
2020-04-27 |
2022-10-25 |
Novo Nordisk A/S |
Semaglutide for use in medicine
|
JP2023524695A
(ja)
|
2020-04-29 |
2023-06-13 |
ノヴォ ノルディスク アー/エス |
Glp-1作動薬およびヒスチジンを含む固形組成物
|
AR122579A1
(es)
*
|
2020-06-12 |
2022-09-21 |
Lilly Co Eli |
Proceso para preparar un agonista dual glp-1 / glucagón
|
CN116157414A
(zh)
|
2020-07-22 |
2023-05-23 |
诺和诺德股份有限公司 |
Glp-1和gip受体共激动剂
|
US20230302150A1
(en)
|
2020-08-20 |
2023-09-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
EP4210680A1
(en)
|
2020-09-07 |
2023-07-19 |
Cyprumed GmbH |
Improved pharmaceutical formulations of glp-1 receptor agonists
|
CN115925995A
(zh)
|
2020-09-30 |
2023-04-07 |
北京质肽生物医药科技有限公司 |
多肽缀合物和使用方法
|
MX2023004672A
(es)
|
2020-11-06 |
2023-07-20 |
Novo Nordisk As |
Profármacos de péptido tipo glucagón humano 1 (glp-1) y usos de los mismos.
|
TW202227474A
(zh)
|
2020-12-18 |
2022-07-16 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1及澱粉素受體之共促效劑
|
CN115124602B
(zh)
|
2021-03-25 |
2024-01-26 |
博瑞生物医药(苏州)股份有限公司 |
Gip和glp-1的双受体激动剂、药物组合物及用途
|
KR20240004342A
(ko)
|
2021-04-03 |
2024-01-11 |
암브룩스, 인코포레이티드 |
항-her2 항체-약물 접합체 및 이의 용도
|
TW202304500A
(zh)
|
2021-04-21 |
2023-02-01 |
瑞士商諾華公司 |
升糖素樣肽化合物
|
KR20240021212A
(ko)
|
2021-06-10 |
2024-02-16 |
안타그 테라퓨틱스 에이피에스 |
비만 및 비만-관련 장애의 치료
|
WO2022270956A1
(ko)
|
2021-06-23 |
2022-12-29 |
주식회사 펩트론 |
세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물
|
EP4360645A1
(en)
*
|
2021-06-25 |
2024-05-01 |
Gan & Lee Pharmaceuticals Co., Ltd. |
Pharmaceutical composition containing glp-1 compound
|
CN117580583A
(zh)
|
2021-06-25 |
2024-02-20 |
甘李药业股份有限公司 |
Pcsk9抑制剂和glp-1受体激动剂的药物组合
|
WO2023285347A1
(en)
|
2021-07-12 |
2023-01-19 |
Novo Nordisk A/S |
Novel fatty acid modified urocortin 2 derivatives and the uses thereof
|
WO2023285580A1
(en)
|
2021-07-15 |
2023-01-19 |
Novo Nordisk A/S |
Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
CN116410297A
(zh)
*
|
2021-07-19 |
2023-07-11 |
内蒙古博睿精创科技有限公司 |
长效glp-1多肽类似物及其制备方法和应用
|
WO2023012263A1
(en)
|
2021-08-04 |
2023-02-09 |
Novo Nordisk A/S |
Solid oral peptide formulations
|
JPWO2023038039A1
(no)
|
2021-09-08 |
2023-03-16 |
|
|
AR127945A1
(es)
|
2021-12-13 |
2024-03-13 |
Novo Nordisk As |
Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina
|
WO2023110758A1
(en)
|
2021-12-13 |
2023-06-22 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
WO2023169456A1
(en)
|
2022-03-09 |
2023-09-14 |
Gasherbrum Bio , Inc. |
Heterocyclic glp-1 agonists
|
WO2023179542A1
(en)
|
2022-03-21 |
2023-09-28 |
Gasherbrum Bio , Inc. |
5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
|
WO2023187067A1
(en)
|
2022-03-30 |
2023-10-05 |
Novo Nordisk A/S |
Formulation method
|
WO2023198140A1
(en)
|
2022-04-14 |
2023-10-19 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
TW202346324A
(zh)
|
2022-05-10 |
2023-12-01 |
丹麥商諾佛 儂迪克股份有限公司 |
前藥及其用途
|
WO2023227505A1
(en)
|
2022-05-23 |
2023-11-30 |
Ascendis Pharma Growth Disorders A/S |
Liquid pharmaceutical formulations of cnp compounds
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|
WO2024079043A1
(en)
|
2022-10-10 |
2024-04-18 |
Bachem Holding Ag |
Method of manufacturing a peptide with a lysine derivative
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
CN116159027A
(zh)
*
|
2022-12-29 |
2023-05-26 |
江苏诺泰澳赛诺生物制药股份有限公司 |
一种司美格鲁肽冻干药物组合物及其制备方法
|